Avalon Pharma (Middle East Pharmaceutical)
4016.SR
#7279
Rank
NZ$0.96 B
Marketcap
NZ$27.51
Share price
-0.33%
Change (1 day)
-46.20%
Change (1 year)

Earnings for Avalon Pharma (Middle East Pharmaceutical) (4016.SR)

Earnings in 2026 (TTM): NZ$53.26 Million

According to Avalon Pharma (Middle East Pharmaceutical)'s latest financial reports the company's current earnings are NZ$0.13 Billion. In 2025 the company made an earning of NZ$49.96 Million, an increase over its 2024 earnings that were of NZ$41.91 Million. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.

Earnings history for Avalon Pharma (Middle East Pharmaceutical) from 2024 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$53.26 M6.62%
2025 NZ$49.96 M19.18%
2024 NZ$41.91 M